Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ng

Showing results (311-320 of 321) with videos related to

Pageof 33
Sort By:
Environmental Science & Technology Letters|August 19, 2024
Zürich II Statement on Per- and Polyfluoroalkyl Substances (PFASs): Scientific and Regulatory NeedsJamie C DeWitt, Juliane Glüge, Ian T Cousins, et al.
Human Molecular Genetics|October 21, 2022
Reclassification of a likely pathogenic Dutch founder variant in KCNH2; implications of reduced penetranceJaël S Copier, Marianne Bootsma, Chai A Ng, et al.
Bioorganic & Medicinal Chemistry Letters|July 17, 2013
Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: prime side chromane-containing inhibitorsRaymond A Ng, Minghua Sun, Simeon Bowers, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 2, 2025
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEYGreco B Malijan, Rebecca J Sardell, Natalie Staplin, et al.
ACS Omega|June 16, 2025
Discovery of Palazestrant (OP-1250), a Potent and Orally Bioavailable Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD)Raymond A Ng, Susanna Barratt, Alison Parisian, et al.
Leukemia|February 15, 2013
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantationG M Marshall, L Dalla Pozza, R Sutton, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 20, 2018
Identification of chronic obstructive pulmonary disease subgroups in 13 Asian citiesW J Kim, V Gupta, M Nishimura, et al.
Journal of Medicinal Chemistry|September 20, 2022
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis TherapyJeffrey J Jackson, Grant M Shibuya, Buvana Ravishankar, et al.
The New England Journal of Medicine|November 4, 2022
Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
The New England Journal of Medicine|October 25, 2024
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
Pageof 33

Showing results (311-320 of 321) with videos related to

Sort By:
Pageof 33
Environmental Science & Technology Letters|August 19, 2024
Zürich II Statement on Per- and Polyfluoroalkyl Substances (PFASs): Scientific and Regulatory NeedsJamie C DeWitt, Juliane Glüge, Ian T Cousins, et al.
Human Molecular Genetics|October 21, 2022
Reclassification of a likely pathogenic Dutch founder variant in KCNH2; implications of reduced penetranceJaël S Copier, Marianne Bootsma, Chai A Ng, et al.
Bioorganic & Medicinal Chemistry Letters|July 17, 2013
Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: prime side chromane-containing inhibitorsRaymond A Ng, Minghua Sun, Simeon Bowers, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 2, 2025
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEYGreco B Malijan, Rebecca J Sardell, Natalie Staplin, et al.
ACS Omega|June 16, 2025
Discovery of Palazestrant (OP-1250), a Potent and Orally Bioavailable Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD)Raymond A Ng, Susanna Barratt, Alison Parisian, et al.
Leukemia|February 15, 2013
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantationG M Marshall, L Dalla Pozza, R Sutton, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 20, 2018
Identification of chronic obstructive pulmonary disease subgroups in 13 Asian citiesW J Kim, V Gupta, M Nishimura, et al.
Journal of Medicinal Chemistry|September 20, 2022
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis TherapyJeffrey J Jackson, Grant M Shibuya, Buvana Ravishankar, et al.
The New England Journal of Medicine|November 4, 2022
Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
The New England Journal of Medicine|October 25, 2024
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
Pageof 33